Alpha Signal Monitor - Daily Market Briefing | February 04, 2026
Daily Market Research Report
February 04, 2026
Alpha Signal Monitor
Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.
Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts
Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM
This report is generated using advanced AI research capabilities with real-time market data access.
Gold ETFs: Institutional Outlook as of February 4, 2026
Trading Idea: Buy Rationale (TL;DR): Institutional consensus remains skewed bullish for gold into 2026 on sustained central‑bank buying, resilient investor demand (including ETFs), and an easier Fed/softer real‑rate backdrop; only Citi is notably cautious near term. With most houses pointing to $4,400–$5,400+ in 2026 (and JPMorgan longer‑term upside), we favor accumulating broad gold ETF exposure (GLD, IAU, BAR) on volatility.
After a record 2025 surge and a sharp bout of early‑2026 volatility, major banks still see higher gold levels into year‑end 2026, anchored by official‑sector accumulation, renewed ETF inflows, and a disinflationary but rate‑cutting macro that keeps real yields contained.
Key Drivers - Persistent central‑bank purchases and reserve diversification away from FX into gold. - Renewed net inflows to gold ETFs as policy rates fall and real yields decline. - Portfolio demand for debasement and geopolitical hedging amid tariff/policy uncertainty. - Constrained mine supply response relative to price gains. - Weak/price‑sensitive jewelry demand partly offset by investment/official demand. - Dollar softness on balance as global easing progresses.
| Institution | Stance | Price View | Key Evidence | Last Update | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Positive/Bullish | $4,900 by Dec‑2026; $4,000 by mid‑2026 | GS Research sees upside skew driven by structural official‑sector accumulation and rising ETF demand as the Fed eases. | 2025-10-07 | (tradingview.com) |
| Morgan Stanley | Positive | $4,400 by end‑2026 (raised from $3,313) | Expects rally to continue on falling USD, strong ETF/central‑bank demand; notes jewelry demand may soften at high prices. | 2025-10-22 | (morganstanley.com) |
| JP Morgan | Bullish | Average ~$5,055/oz in Q4‑2026; potential toward ~$6,000+ longer term (2027) | Structural bull case on sustained official‑reserve and investor diversification; demand not linear but trends intact. | 2025-12-16 | (jpmorgan.com) |
| Bank of America | Bullish | Path to $5,000 in 2026; 2026 average around ~$4,400 | Sees a further leg higher if investment demand rises ~14% y/y; acknowledges near‑term correction risk. | 2025-10-13 | (investing.com) |
| Citigroup | Neutral/Cautious near term | 2026 average ~$3,250; trimmed 0–3m target to ~$3,800 (Oct‑2025) | Softer momentum and potential easing of macro risks could cap prices; still sees strategic hedge case medium/long term. | 2025-10-28 | (investing.com) |
| UBS | Most Preferred/Overweight (CIO) | Base‑case $5,000 reached; watching upside risk case ~$5,400; maintains ~5% strategic allocation to gold | Views early‑Feb pullback as volatility within a structural uptrend; central‑bank demand and lower real rates remain supportive; reiterates ~5% allocation as portfolio hedge. | 2026-02-02 | (ubs.com) |
| HSBC | Bullish | High near ~$5,000 in 1H‑2026; 2026 average lifted to ~$4,600 | Forecast supported by geopolitical/policy uncertainty, rising public debt, and stickier new investor cohorts. | 2025-10-17 | (business-standard.com) |
| Deutsche Bank | Positive | Year‑end 2026 forecast ~$4,500/oz (CIO) | Sees further upside for gold in 2026 on central‑bank demand and hedging demand alongside AI‑led equity cycle. | 2025-11-26 | (db.com) |
Risk Considerations - Hawkish Fed turn or stronger USD that lifts real yields and pressures gold/ETFs. - Rapid détente in geopolitical/trade tensions that fades safe‑haven and policy‑uncertainty bids. - ETF outflows or a sharp speculative positioning unwind after the 2025 run‑up. - Demand destruction at elevated prices (notably jewelry/EM retail); China demand variability. - Liquidity/volatility shocks or regulatory changes affecting bullion/ETF market plumbing.
Bias to add on dips across GLD/IAU/BAR, sizing as a core hedge rather than a tactical trade. Use GLD for depth/liquidity or IAU/BAR for fee sensitivity; lean into strength if real yields trend lower and official‑sector buying stays firm, but tighten risk if USD/real rates re‑accelerate or ETF flows turn negative.
Stock Ratings — U.S. Tech Mega-cap: Street Targets and Ratings (as of 2026-02-04)
Notes: ratings normalized to Buy/Hold/Sell equivalents (Overweight=Buy; Equal-Weight=Hold; Underweight=Sell). Dates are last published/updated dates we could verify publicly. Consensus is across the six listed institutions only.
AAPL - Apple Inc.
Broadly bullish across the Street with multiple recent target hikes into/after FYQ1 results; consensus leans Buy with low-$300s average PT.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $330 | 2026-02-03 | Reiterated Buy; cites improving App Store spending trends. | (m.investing.com) |
| Morgan Stanley | Buy | $315 | 2026-01-26 | Raised PT ahead of earnings; Overweight stance maintained. | (9to5mac.com) |
| JP Morgan | Buy | $315 | 2026-01-26 | PT raised from $305; Overweight. | (marketbeat.com) |
| Bank of America | Buy | $325 | 2026-01-12 | Reiterated Buy into Jan. 29 earnings; bullish setup. | (uk.finance.yahoo.com) |
| Citigroup | Buy | $330 | 2025-12-09 | Raised PT on stronger iPhone cycle/upgrade pool. | (investing.com) |
| Wells Fargo | Buy | $290 | 2025-10-21 | Maintains Overweight; PT raised previously. | (gurufocus.com) |
Consensus View - Rating: Buy, Target Price: $318 - All six skew positive (5×Buy/OW, 1×OW considered Buy-equivalent). Avg PT ≈ $317.5.
MSFT - Microsoft Corp.
Despite recent volatility on AI capex/Azure growth debates, large-cap brokers remain constructive with high-$500s/low-$600s targets on average.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $655 | 2026-01-20 | Reiterated Buy; sees multiple AI monetization vectors. | (investing.com) |
| Morgan Stanley | Buy | $650 | 2026-01-14 | Overweight reiterated post CIO survey. | (investing.com) |
| JP Morgan | Buy | $575 | 2025-10-30 | Overweight; PT nudged higher post earnings. | (gurufocus.com) |
| Bank of America | Buy | $520 | 2026-01-26 | Buy; PT trimmed after results. | (marketbeat.com) |
| Citigroup | Buy | $660 | 2026-01-21 | Buy; PT lowered from $690. | (gurufocus.com) |
| Wells Fargo | Buy | $630 | 2026-01-22 | Overweight; PT cut from $665. | (marketbeat.com) |
Consensus View - Rating: Buy, Target Price: $615 - 6/6 Buy/OW equivalents; Avg PT ≈ $615.
GOOGL - Alphabet Inc.
AI execution and remedies backdrop drove broad PT increases into late-2025/early-2026; one Hold-equivalent (WFC) with higher PT.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $375 | 2026-01-13 | Maintained Buy; PT raised on improving outlook. | (gurufocus.com) |
| Morgan Stanley | Buy | $270 | 2025-10-02 | Overweight; PT raised during Oct-2025 update cycle. | (gurufocus.com) |
| JP Morgan | Buy | $300 | 2025-10-27 | Overweight; PT increased on AI strength and legal clarity. | (gurufocus.com) |
| Bank of America | Buy | $280 | 2025-10-20 | Buy; ad strength cited into earnings. | (investing.com) |
| Citigroup | Buy | $229 | 2025-02-05 | Buy maintained with revised PT post earnings. | (investing.com) |
| Wells Fargo | Hold | $350 | 2026-01-12 | Equal-Weight; PT raised materially. | (gurufocus.com) |
Consensus View - Rating: Buy, Target Price: $301 - 5×Buy vs 1×Hold; Avg PT ≈ $300.7.
AMZN - Amazon.com Inc.
Street remains positive with PTs clustering in the high-$200s, reflecting AWS re-acceleration and ad growth; latest BAC trim still implies upside.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $290 | 2025-12-05 | PT lifted post re:Invent; AWS/AI positioning highlighted. | (investing.com) |
| Morgan Stanley | Buy | $300 | 2025-07-10 | Overweight; PT raised on tariff/backdrop improvement. | (m.investing.com) |
| JP Morgan | Buy | $255 | 2025-07-11 | Overweight; PT raised following better outlook. | (gurufocus.com) |
| Bank of America | Buy | $286 | 2026-01-27 | Buy; PT trimmed ahead of Feb. 5 earnings. | (uk.investing.com) |
| Citigroup | Buy | $273 | 2025-02-07 | Buy maintained after Q4 results. | (investing.com) |
| Wells Fargo | Buy | $295 | 2025-12-02 | Overweight; modest PT increase on AWS capacity build. | (investing.com) |
Consensus View - Rating: Buy, Target Price: $283 - 6/6 Buy/OW equivalents; Avg PT ≈ $283.2.
Highlights
- Apple: Goldman Sachs reiterated Buy with a $330 PT on Feb 3, 2026; JPMorgan and Morgan Stanley each at $315 (Jan 26, 2026).
- Microsoft: GS at $655 (Jan 20, 2026) and MS at $650 (Jan 14, 2026) both reaffirm Buy/OW despite post-earnings volatility.
- Alphabet: Goldman lifted PT to $375 (Jan 13, 2026); Wells Fargo Equal-Weight but raised PT to $350 (Jan 12, 2026).
- Amazon: BAC trimmed PT to $286 (Jan 27, 2026) but stance remains Buy; GS at $290; MS at $300.
If you’d like, I can continue with NVDA, META, TSLA, AVGO, and TSM next and compute updated consensus once all six institutions are captured for each.
IPO Calendar
Timeframe: February 4, 2026 to March 4, 2026
Active first-half February slate led by a large industrial/AI‑infrastructure play (Forgent Power Solutions), a pair of sizeable consumer names (Bob’s Discount Furniture and Once Upon a Farm), adtech (Liftoff Mobile), and multiple biopharmas (Veradermics, Eikon, Agomab; SpyGlass expected). Calendars beyond mid‑February remain fluid; IPO dates are rarely set more than 7–10 days in advance. (barrons.com)
Veradermics, Incorporated (MANE)
- Expected listing date: February 4, 2026
- Price range: Final pricing: $17.00 per share
- Shares offered: 15,077,647 primary shares (greenshoe up to 2,261,647)
- Exchange: NYSE
- Lead underwriters: Jefferies, Leerink Partners, Citigroup, Cantor Fitzgerald
- Business summary: Dermatologist‑founded, late clinical‑stage biopharma developing therapies for prevalent aesthetic and dermatologic conditions; lead asset is an oral, extended‑release minoxidil (VDPHL01) for male and female pattern hair loss.
- Notes: IPO priced the evening of February 3, 2026; trading expected to begin February 4, 2026 and closing February 5, 2026. Details per issuer’s Business Wire pricing announcement and contemporaneous reports. (markets.financialcontent.com)
- Sources: Business Wire: “Veradermics Announces Pricing of Upsized Initial Public Offering” (Feb 3, 2026), RTT News summary (Feb 4, 2026)
Bob’s Discount Furniture, Inc. (BOBS)
- Expected listing date: February 5, 2026 (expected)
- Price range: $17.00 – $19.00
- Shares offered: 19,450,000 shares (overallotment 2,917,500 by selling stockholder)
- Exchange: NYSE
- Lead underwriters: J.P. Morgan, Morgan Stanley, RBC Capital Markets, UBS Investment Bank, BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Robert W. Baird, KeyBanc Capital Markets, Raymond James, AmeriVet Securities, Loop Capital Markets, R. Seelaus & Co., LLC, Ramirez & Co., Inc.
- Business summary: National value‑focused, omnichannel furniture retailer with 206 showrooms across 26 U.S. states; proceeds to prepay term‑loan debt; company will remain a controlled company majority‑owned by Bain Capital after the IPO.
- Notes: Terms and underwriter roster from the SEC preliminary prospectus dated January 26, 2026; NYSE listing under “BOBS.” (sec.gov)
- Sources: SEC preliminary prospectus (Jan 26, 2026): Bob’s Discount Furniture, Inc. (Form S‑1)
Eikon Therapeutics, Inc. (EIKN)
- Expected listing date: February 5, 2026 (expected)
- Price range: $16.00 – $18.00
- Shares offered: 17,648,000 primary shares (underwriters’ option up to 2,647,200)
- Exchange: Nasdaq Global Market
- Lead underwriters: J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, Mizuho
- Business summary: Clinical‑stage oncology company integrating advanced engineering and single‑molecule imaging; lead TLR7/8 agonist EIK1001 in global Phase 2/3 for advanced melanoma and in NSCLC studies.
- Notes: Terms, exchange and underwriters per amended SEC S‑1/A filed January 28, 2026; valuation context covered by Reuters. (sec.gov)
- Sources: SEC Form S‑1/A (Jan 28, 2026): Eikon Therapeutics, Inc., Reuters coverage of terms/valuation (Jan 28, 2026)
Forgent Power Solutions, Inc. (FPS)
- Expected listing date: February 5, 2026 (expected)
- Price range: $25.00 – $29.00
- Shares offered: 56,000,000 total (16,586,823 primary; 39,413,177 secondary); greenshoe up to 2,488,023 primary and 5,911,977 secondary
- Exchange: NYSE
- Lead underwriters: Goldman Sachs, Jefferies, Morgan Stanley, J.P. Morgan, BofA Securities, Barclays, TD Cowen, MUFG, Wolfe | Nomura Alliance, KeyBanc Capital Markets, Oppenheimer & Co.
- Business summary: Designer/manufacturer of engineered electrical distribution equipment for data centers, grid and energy‑intensive industrial facilities; demand levered to cloud/AI data‑center buildouts and grid upgrades.
- Notes: Roadshow launch press release (Jan 26, 2026) and SEC S‑1/A (Jan 16, 2026) provide range, share split, ticker and underwriters; listing subject to pricing/market conditions. (forgentpower.com)
- Sources: Company press release (Jan 26, 2026): “Forgent Power Solutions Announces Launch of Initial Public Offering”, SEC Form S‑1/A (Jan 16, 2026): Forgent Power Solutions, Inc.
QDRO Acquisition Corp. (QADR)
- Expected listing date: February 5, 2026 (estimated)
- Price range: $10.00 per unit (1 share + 1/2 warrant)
- Shares offered: 20,000,000 units (up to 23,000,000 incl. OA)
- Exchange: Nasdaq
- Lead underwriters: Cantor Fitzgerald & Co. (representative)
- Business summary: Special purpose acquisition company targeting financial services and adjacent sectors.
- Notes: S‑1/A filed January 20, 2026; final effectiveness/listing timing not yet posted at exchanges as of February 4, 2026. Date and size may shift at pricing. (sec.gov)
- Sources: SEC Form S‑1/A (Jan 20, 2026): QDRO Acquisition Corp., Law Insider excerpt (underwriting agreement identifying Cantor Fitzgerald as representative)
Liftoff Mobile, Inc. (LFTO)
- Expected listing date: February 6, 2026 (expected)
- Price range: $26.00 – $30.00
- Shares offered: 25,400,000 primary shares (underwriters’ option 3,810,000 from selling stockholders)
- Exchange: Nasdaq Global Select Market
- Lead underwriters: Goldman Sachs & Co. LLC, Jefferies, Morgan Stanley, (additional joint bookrunners and co‑managers per press release)
- Business summary: Performance marketing and monetization platform for the mobile app economy, offering AI‑enabled advertising and measurement solutions to app developers and brands.
- Notes: Company roadshow launch press release provides terms, exchange and full syndicate; listing contingent on SEC effectiveness and market conditions. (prnewswire.com)
- Sources: PR Newswire: “Liftoff Announces Launch of Initial Public Offering” (Jan 29, 2026)
Once Upon a Farm, PBC (OFRM)
- Expected listing date: February 6, 2026 (expected)
- Price range: $17.00 – $19.00
- Shares offered: 10,997,209 total (7,631,537 primary; 3,365,672 secondary); greenshoe 1,649,581
- Exchange: NYSE
- Lead underwriters: Goldman Sachs & Co. LLC, J.P. Morgan, BofA Securities, William Blair
- Business summary: Public Benefit Corporation producing organic, cold‑pressed baby and kids’ foods sold DTC and through major retailers; proceeds to repay credit facility and invest in equipment/operations.
- Notes: Approved to list on NYSE under “OFRM.” Terms from SEC S‑1/A and issuer roadshow press release dated January 26, 2026. (sec.gov)
- Sources: SEC Form S‑1/A (Jan 26, 2026): Once Upon a Farm, PBC, Business Wire (via FinancialContent): “Once Upon a Farm Announces Launch of Initial Public Offering” (Jan 26, 2026)
AgomAb Therapeutics NV (AGMB)
- Expected listing date: February 6, 2026 (expected)
- Price range: $15.00 – $17.00 (ADSs)
- Shares offered: 12,500,000 ADSs (30‑day option up to 1,875,000 ADSs)
- Exchange: Nasdaq
- Lead underwriters: J.P. Morgan, Morgan Stanley, Leerink Partners, Van Lanschot Kempen
- Business summary: Belgian clinical‑stage biotech developing disease‑modifying therapies for immunology/inflammatory diseases; lead program ontunisertib (AGMB‑129) for fibrostenosing Crohn’s disease; additional program AGMB‑447 for IPF.
- Notes: Issuer launch press release (Feb 2, 2026) and Reuters terms/valuation coverage; timing subject to pricing and SEC effectiveness. (globenewswire.com)
- Sources: GlobeNewswire: “Agomab Announces Launch of Initial Public Offering” (Feb 2, 2026), Reuters coverage of terms/valuation (Jan 29, 2026)
SpyGlass Pharma, Inc. (SGP)
- Expected listing date: February 6, 2026 (expected)
- Exchange: Nasdaq Global Select Market
- Business summary: Late‑stage ophthalmology company developing sustained‑release drug delivery for glaucoma and ocular hypertension; lead BIM‑IOL System integrates drug pads with an intraocular lens for multi‑year bimatoprost delivery at time of cataract surgery.
- Notes: Company filed initial S‑1 on Jan 16, 2026. Several market calendars indicate a Feb 6 target and provisional terms (e.g., 9.375M shares at $15–$17), but final terms, banks and size were not in an amended SEC filing as of Feb 4; treat date/sizing as tentative. (sec.gov)
- Sources: SEC Form S‑1 (Jan 16, 2026): SpyGlass Pharma, Inc., IPOX calendar entry (Feb 6, 2026)
AGI Inc (Agibank) (AGBK)
- Expected listing date: February 11, 2026 (tentative)
- Price range: $15.00 – $18.00
- Shares offered: 43,636,364 Class A shares (option up to 6,545,455)
- Exchange: NYSE
- Lead underwriters: Goldman Sachs, Morgan Stanley, Citigroup, (Brazilian co‑bookrunners noted in coverage: Bradesco BBI, BTG Pactual, Itaú BBA, Santander, Société Générale, XP)
- Business summary: Brazil‑focused, technology‑enabled bank targeting underserved consumers (e.g., social‑security beneficiaries and public/private‑sector workers) with secured/payload‑linked credit and adjacent financial services via digital channels and 1,100+ ‘Smart Hubs.’
- Notes: Sizing and range per recent F‑1/F‑1/A disclosures reported by wire services; calendar timing remains subject to SEC effectiveness and market conditions; exact U.S. listing date could move. (renaissancecapital.com)
- Sources: Renaissance Capital issuer/news page summarizing filing terms, IPOX calendar entry (AGI)
All dates, ranges and share counts are as of the morning of Wednesday, February 4, 2026, and are subject to SEC effectiveness, exchange approvals and market conditions. Many issuers set pricing/trade dates only 1–2 days ahead; offerings may be upsized, downsized, delayed or withdrawn.
Sources
- Stock Ratings: https://9to5mac.com/2026/01/26/jp-morgan-boosts-apple-price-target-echoing-recent-morgan-stanley-hike/?utm_source=openai, https://m.investing.com/news/analyst-ratings/goldman-sachs-reiterates-buy-rating-on-apple-stock-with-330-price-target-93CH-4482636?ampMode=1&utm_source=openai, https://m.investing.com/news/analyst-ratings/morgan-stanley-raises-amazon-stock-price-target-to-300-on-lower-tariffs-93CH-4130982?ampMode=1&utm_source=openai, https://uk.finance.yahoo.com/news/bofa-sees-bullish-setup-earnings-182208376.html?utm_source=openai, https://uk.investing.com/news/analyst-ratings/amazon-stock-price-target-lowered-to-286-by-bofa-on-aws-outlook-93CH-4471214?utm_source=openai, https://www.gurufocus.com/news/2972940/jp-morgan-raises-price-target-for-amazon-amzn-to-255--amzn-stock-news?utm_source=openai, https://www.gurufocus.com/news/3129107/googl-morgan-stanley-raises-price-target-to-270-maintains-overweight-rating-googl-stock-news?mobile=true&utm_source=openai, https://www.gurufocus.com/news/3152412/aapl-wells-fargo-raises-price-target-to-290-maintains-overweight-rating-aapl-stock-news?utm_source=openai, https://www.gurufocus.com/news/3161739/alphabet-goog-analyst-ratings-jp-morgan-raises-price-target-goog-stock-news?utm_source=openai, https://www.gurufocus.com/news/3173478/jp-morgan-raises-microsoft-msft-price-target-to-575-msft-stock-news?utm_source=openai, https://www.gurufocus.com/news/4106624/googl-wells-fargo-raises-alphabets-target-price-to-350-googl-stock-news?utm_source=openai, https://www.gurufocus.com/news/4109066/googl-goldman-sachs-maintains-buy-rating-raises-price-target-googl-stock-news?utm_source=openai, https://www.gurufocus.com/news/8540817/msft-citigroup-lowers-price-target-to-660-while-maintaining-buy-rating-msft-stock-news?utm_source=openai, https://www.investing.com/news/analyst-ratings/amazon-stock-price-target-raised-to-295-from-292-at-wells-fargo-93CH-4385725?utm_source=openai, https://www.investing.com/news/analyst-ratings/bofa-securities-raises-alphabet-stock-price-target-to-280-on-ad-strength-93CH-4296307?utm_source=openai, https://www.investing.com/news/analyst-ratings/citi-cuts-alphabet-price-target-to-229-maintains-buy-rating-93CH-3849913?utm_source=openai, https://www.investing.com/news/analyst-ratings/citi-cuts-amazon-stock-price-target-to-273-maintains-buy-rating-93CH-3855841?utm_source=openai, https://www.investing.com/news/analyst-ratings/goldman-sachs-reiterates-buy-rating-on-amazon-stock-cites-aws-ai-positioning-93CH-4392797?utm_source=openai, https://www.investing.com/news/analyst-ratings/microsoft-stock-price-target-maintained-at-655-by-goldman-sachs-93CH-4454081?utm_source=openai, https://www.investing.com/news/analyst-ratings/morgan-stanley-reiterates-overweight-rating-on-microsoft-stock-at-650-93CH-4446158?utm_source=openai, https://www.investing.com/news/stock-market-news/citi-raises-apple-price-target-on-firmer-upgrade-cycle-iphone-17-strength-4398652?utm_source=openai, https://www.marketbeat.com/instant-alerts/apple-nasdaqaapl-price-target-raised-to-31500-at-jpmorgan-chase-co-2026-01-26/?utm_source=openai, https://www.marketbeat.com/instant-alerts/microsoft-nasdaqmsft-price-target-lowered-to-63000-at-wells-fargo-company-2026-01-22/?utm_source=openai, https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/?utm_source=openai
- IPO Calendar: https://markets.financialcontent.com/stocks/article/bizwire-2026-2-4-veradermics-announces-pricing-of-upsized-initial-public-offering?utm_source=openai, https://www.barrons.com/articles/ipo-market-stock-listings-e0c6b6f0?utm_source=openai, https://www.forgentpower.com/articles/forgent-power-solutions-announces-launch-of-initial-public-offering?utm_source=openai, https://www.globenewswire.com/news-release/2026/02/02/3230139/0/en/Agomab-Announces-Launch-of-Initial-Public-Offering.html?utm_source=openai, https://www.prnewswire.com/news-releases/liftoff-announces-launch-of-initial-public-offering-302674271.html, https://www.renaissancecapital.com/IPO-Center/News/116158/Brazilian-consumer-bank-AGI-files-for-an-estimated-%24200-million-US-IPO?utm_source=openai, https://www.sec.gov/Archives/edgar/data/0002083217/000121390026005657/0001213900-26-005657-index.htm, https://www.sec.gov/Archives/edgar/data/1696556/000119312526021667/d832753ds1a.htm, https://www.sec.gov/Archives/edgar/data/1778922/000162828026002356/spyglass-sx1.htm?utm_source=openai, https://www.sec.gov/Archives/edgar/data/1861123/000119312526025565/d903262ds1a.htm, https://www.sec.gov/Archives/edgar/data/2085187/000162828026003358/bobsdiscountfurnitureincs-.htm
Disclaimer
This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.
Generated on: 2026-02-04 at 11:23 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.
Powered by Alpha Signal Monitor | Market Intelligence Through AI